ArticleScientific reports2025
A novel cancer-associated membrane signature predicts prognosis and therapeutic response for lung adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrative multimodal transcriptomics identifies a cancer-associated fibroblast membrane signature for predicting prognosis and therapeutic response in pancreatic ductal adenocarcinoma.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Parthenolide and Its Derivatives in the Treatment of Respiratory Tract Diseases: Therapeutic Effects and Molecular Mechanisms.Drug design, development and therapy · 2026Review
- A clinical and CT-based model for differentiating high-grade from low-grade lung adenocarcinoma in patients with idiopathic pulmonary fibrosis.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) is a leading cause of cancer-related death, and reliable biomarkers for prognosis and treatment guidance remain limited. Membrane proteins play key roles in tumor progression and therapeutic response, yet their clinical utility in LUAD remains underexplored. We integrated scRNA-seq, spatial transcriptomics, and bulk RNA-seq datasets from multiple LUAD cohorts to identify cancer-specific membrane proteins derived from epithelial subpopulations. Based on these results, we constructed a prognostic signature, LCaMPS, and evaluated its predictive performance using multiple datasets. The expression of model genes was confirmed at both the bulk RNA and protein levels. Associations with the tumor microenvironment (TME) and drug sensitivity were further analyzed. A distinct LUAD-enriched epithelial cluster (Epi_c0) exhibiting hypoxic and EMT signatures was identified. 35 cancer-specific membrane proteins were defined, several of which, including TSPAN8, BACE2, and COX16, showed strong spatial localization within the tumor regions. LCaMPS, a 9-membrane gene-based prognostic model, stratified patient prognosis and predicted 5- and 10-year survival rates with high accuracy. High LCaMPS scores were associated with increased infiltration of neutrophils, endothelial cells, and fibroblasts in the TME and predicted higher sensitivity to 66 chemotherapeutic agents, including Gemcitabine and Sorafenib. Low-risk patients were predicted to respond better to drugs, such as Cisplatin and Parthenolide. This study highlights the importance of membrane expression patterns in LUAD at single-cell and spatial resolution. The LCaMPS model provides a robust prognostic and therapeutic stratification tool with potential applications in personalized cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.